Skip to Content

ABP 710 Approval Status

FDA Approved: No
Brand name: ABP 710
Generic name: biosimilar infliximab
Company: Amgen Inc.
Treatment for: Rheumatoid Arthritis, Plaque Psoriasis, Crohn's Disease, Maintenance, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis

ABP 710 (biosimilar infliximab) is a tumor necrosis factor (TNF) blocker biosimilar to Remicade (infliximab) in development for the treatment of rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and ankylosing spondylitis.

Development Status and FDA Approval Process for ABP 710

DateArticle
Dec 17, 2018Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide